Brisbane Times
·general
·1 hour ago
WA biotech duo takes aim at diabetes beyond Ozempic
A Western Australian biotech duo is developing RNA-based therapies targeting insulin resistance in type 2 diabetes, aiming to address limitations of GLP-1 drugs like Ozempic. ProGenis Pharmaceuticals and Perth-based Syngenis Labs use antisense oligonucleotide technology to intervene at the cellular level, potentially improving insulin sensitivity where existing therapies fall short.
Summary by Glance · Brisbane Times
Newer
Next
Loving doing this? 🎉
Take it further — get the full app and never miss a moment of what's happening in Australia.
Breaking news alerts
Instant lock-screen notifications the moment big stories break across Australia.
Australian news & events
Politics, sport, weather, local events — all in one swipeable feed, updated around the clock.
Stay ahead of the news cycle
30-second summaries so you're always informed, even on your busiest days.
Loading article…
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
✨
Ask AI